AMR (ASFA category III; Grade 2C). 10 Categorization of additional indications within ASFA guidelines is constrained by the limited availability of outcomes data. 2 Therefore, we undertook a retrospective study of cardiac transplant patients at a single center to define TPE indications and assess clinical outcomes.
| M ATE RI ALS AN D ME THO DS

| Patients and study design
Under an institutional review board-approved protocol, we retrospectively reviewed a prospectively maintained clinical therapeutic apheresis database. We identified all consecutive patients who received TPE between January 1, 2010, and December 31, 2014, for a cardiac transplant indication such as (1) perioperative TPE for suspected positive crossmatch or heparin induced thrombocytopenia or (2) postoperative TPE for positive HLA antibodies, elevated PRA, positive crossmatch, primary graft dysfunction, and/or AMR. Simultaneously, using an institutional electronic search resource, the Duke Enterprise Data Unified Content Explorer (DEDUCE), 11 we identified all consecutive patients who received a cardiac transplant from 2010 to 2014. We included in our study cohort all patients identified as having received both a cardiac transplant and TPE within the 2010 to 2014 study period. We excluded any patients who were transplanted at a center other than Duke University Medical Center (DUMC) or whose 2010-2014 cardiac transplant surgery represented a second or third transplant (re-transplant). We also excluded all TPE procedures performed prior to transplantation. Based on (1) the timing of TPE relative to transplantation and (2) number of TPE procedures, TPE-treated patients were categorized into the following cohorts: cohort 1 received a Single TPE procedure within 24 h of transplantation and was designated the "Single TPE" cohort; cohort 2 received >1 TPE procedure within 24 h of transplantation and was designated the "Multiple TPE" cohort; and cohort 3 received 1 or more TPE procedures beginning >24 h post transplantation and was designated the "Delayed TPE" cohort. Cardiac transplant patients who did not receive TPE within the study period were designated the non-TPE treated or "Zero TPE" cohort and used as the control group for assessment of overall survival.
| TPE protocol
Patients were treated with a standardized TPE protocol to exchange 1.0 plasma volume (PV), calculated using Nadler's formula. 12 The default TPE exchange fluid was Albumin (Albutein ® 5% Solution; Grifols, Durham NC). A 100% albumin exchange was typically performed except in the following cases: when TPE was done within 3 days of a surgical procedure; when pre-TPE fibrinogen was <100 mg/dL; on the third consecutive day of daily TPE; and in any patient in whom clinical bleeding risk was felt to be increased due to ongoing therapeutic anticoagulation. In these cases, plasma or a combination of albumin and plasma was used. 
| Data collection and statistical analysis
We abstracted patient-level study data from the electronic medical record into Research Electronic Data Capture (REDCap), a secure web-based application designed to support data capture for research studies. 13 We recorded demo- Results of multivariable modeling are presented as hazard ratios (HR), 95% confidence intervals, and P-values. All P-values were 2-sided and considered significant at the nominal .05 level (i.e., P values <.05). Statistical analyses were performed using GraphPad prism ® (GraphPad Software, Inc., La Jolla, CA, v7.0b) and R 3.4.0 (R Core Team (2017), https://www.R-project.org) using the Survival Package.
| R ESULT S
| Patient characteristics
Of 333 orthotopic heart transplant patients, 313 were eligible for analysis and 109 were treated with TPE. The flowchart for patient selection and outcomes reporting is shown in Figure 1 . Demographics of the non TPE versus TPE-treated study cohorts are shown in Table 1 . When compared to the non TPE-treated cohort, the TPE-treated cohort had a higher percentage of females (46 vs. 23%; P < .0001) and Blacks/ African Americans (44 vs. 23%; P 5 .0009). Three patients in the non TPE-treated cohort underwent combined heart/lung transplant compared to 1 patient in the TPE-treated cohort. One patient in the TPE-treated cohort underwent a combined heart/kidney transplant.
| Outcomes by TPE cohort
As illustrated in Figure 1 , there were 40, 42, and 27 patients in the Single, Multiple, and Delayed TPE cohorts, respectively. These 3 cohorts were similar in respect to age, sex, and transplant indication (see Table 2 ).
| Single TPE cohort
For all patients, perioperative TPE was performed once at the time of transplantation. Most patients underwent TPE due to an elevated PRA or positive HLA antibodies (N 5 27; 68%), followed by a variety of other causes, including 5 patients (12%) with suspected HLA antibodies but eventual negative crossmatch, 5 patients (12%) with heparin-induced thrombocytopenia (HIT), and 3 patients (8%) with unclear indication.
With regards to medical therapy on the day of the TPE procedure, all patients received methylprednisolone. Thirtyeight patients (95%) received basiliximab. Of the remaining 2 patients not treated with basiliximab, one (3%) received rabbit Antithymocyte Globulin (rATG) and the other rituximab. Twenty-two patients (55%) received a dose of standard immunosuppression (21 patients received mycophenolate and 1 patient received cyclosporine).
Thirty-day post-transplant infection occurred in 16 patients (40%). Ten patients had only 1 infection (6 with CMV viremia and 4 with positive bacterial cultures) and 6 patients had 2
F IGUR E 1 Schema of patient selection. Of 333 patients transplanted within the study period, 1 incorrectly classified lung only transplant patient was excluded. Also excluded were 14 patients transplanted at a center other than Duke University Medical Center (DUMC) and 5 patients who received a second or third heart transplant. Of the 313 evaluable patients, 204 did not receive TPE within the study period (Zero TPE cohort) and 109 did. Of these 109 TPE-treated patients, 82 received TPE within 24 h of transplantation with 40 patients receiving a Single TPE procedure (Single TPE cohort) and 42 patients receiving Multiple TPE procedures (Multiple TPE cohort); an additional 27 patients received 1 or more TPE procedures beginning >24 h post transplantation (Delayed TPE cohort) 
| Multiple TPE cohort
Therapeutic plasma exchange was used to treat a positive crossmatch in 26 patients (62%), elevated PRA or positive HLA antibodies in 8 patients (19%), primary graft dysfunction/AMR in 7 patients (17%), and suspected but eventually negative crossmatch in 1 Patient (2%).
The most common TPE schedule was daily in 36 patients (86%) followed by daily with 1 skipped/missed day in 6 patients (14%). With regards to number of TPE procedures, most patients (N 5 28; 67%) received 5 TPE. In descending order of number of TPE procedures, 6 patients (14%) received 6 TPE, 2 patients (5%) received 4 TPE, 1 Patient (2%) received 3 TPE and 5 patients (12%) received 2 TPE. Of the 5 patients who received only 2 TPE, 4 were stopped early due to negative crossmatch results and 1 died after the second TPE procedure.
We also analyzed the number of procedures by TPE indication. The 7 patients with primary graft dysfunction/AMR were all treated the same with an average of 5 TPE procedures (all but 1 patient who died after the second procedure received 5 TPE). The 26 patients with a positive crossmatch received an average of 5 procedures (19 patients received 5 TPE, 6 patients received 6 TPE, and 1 patient received 4 TPE). The greatest variation in procedure number occurred in the 8 patients treated for positive PRA or HLA antibodies with an average of 3.5 TPE procedures (3 patients each received 2 and 5 TPE procedures, while 1 patient each received 3 and 4 TPE procedures). Finally, the 1 patient with suspected antibodies stopped TPE after only 2 procedures when antibody testing returned negative.
All patients received methylprednisolone and standard immunosuppression with 33 patients (79%) receiving mycophenolate 1 tacrolimus, 8 patients (19%) receiving mycophenolate alone, and 1 Patient (2%) receiving tacrolimus alone. Thirty-eight patients (90%) received basiliximab and 1 Patient (2%) received rituximab. Eleven patients (26%) were treated with an immune globulin, with 8 receiving IVIG and 3 receiving rATG. Thirty-day post-transplant infection occurred in 17 patients (40%) as follows: 10 patients had only 1 infection (8 with positive bacterial cultures, 1 with CMV viremia, and 1 with Clostridium difficile); 6 patients had 2 infections (3 with positive bacterial cultures and CMV viremia, 2 with positive bacterial cultures and sternal wound infection, and 1 with positive bacterial cultures and Clostridium difficile); 1 patient had 3 infections (positive bacterial cultures, sternal wound infection, and Clostridium difficile).
| Delayed TPE cohort
In all patients, TPE was primarily used to treat AMR. The median time from transplantation to first TPE episode was 245 days (2-1368 days).
The most common TPE schedule was daily in 20 patients (74%), followed by daily with 1 skipped/missed day in 3 patients (11%), and other (TPE every 1-3 days) in 4 patients (15%).
Most patients received 5 TPE (N 5 20; 74%); 3 patients (11%) received 4 TPE; 2 patients (7%) received 3 TPE; and 1 Patient (4%) received 7 TPE. One patient (4%) who was planned for daily TPE died after the first procedure. All patients were treated with steroids with the most common agent being methylprednisolone in 25 patients (93%). Additionally, all patients received standard immunosuppressive therapy as follows: mycophenolate 1 tacrolimus in 16 patients (59%); tacrolimus alone in 7 patients (26%); and, in 1 patient each, azathioprine 1 mycophenolate 1 tacrolimus; azathioprine 1 tacrolimus; mycophenolate 1 cyclosporine; or mycophenolate alone. Sixteen patients (59%) were treated with an immune globulin with 10 patients receiving rATG alone (37%) and 3 patients each receiving rATG 1 IVIG (11%) or IVIG alone (11%). Four patients (15%), who were within 5 days of transplantation, received basiliximab and 2 patients (7%) received rituximab.
Post-transplant infection occurred in 9 patients (33%). Eight patients had only 1 infection (6 with a positive bacterial culture, 1 with CMV viremia, and 1 with Clostridium difficile) and 1 patient had 2 infections (positive bacterial culture and CMV viremia).
| Overall and TPE survival outcomes
The median follow-up period was 49 months (4 years). Kaplan-Meier plots for each outcome are shown in Figures 2  and 3 , respectively. Adjusted overall and TPE survival outcome model results are shown in Table 3 .
For the primary outcome, 0 patients underwent a retransplant and 40 patients (37%) died during follow-up. There was a significant overall survival difference between all patient cohorts (Zero, Single, Multiple, and Delayed TPE; P values 5 .005). When compared to the Zero TPE cohort (reference group), there was no significant survival difference for patients in the Single TPE cohort (HR 1.08 [CI, 0.54, 2.14], P 5 .84; see Table 3 ). However, there were significant declines in overall survival for both the Multiple and Delayed TPE cohorts (HR 2.62 [CI, 1.53, 4.49], P 5 .0004 and HR 1.98 [CI, 1.02-3.83], P 5 .04, respectively).
For the secondary outcome, 34 patients (31%) had a repeat TPE episode, 0 patients underwent a re-transplant, and 25 patients (23%) died. There were significant differences between the 3 TPE groups (p 5 0.002). When compared to the Single TPE cohort (reference group), the Multiple TPE cohort had worse TPE survival (HR 2.59 [CI, 1.31-5.14], P 5 .006). The Delayed TPE cohort also had worse TPE survival (HR 3.18 [CI, 1.56, 6 .50], P 5 .002).
| Impact of post-transplant infection
Thirty-day post-transplant infection was independently associated with overall survival (HR 2.31 [CI, 1.50, 3.54], P 5 .0001) but did not achieve statistical significance for TPE survival (HR 1.64 [CI, 0.97, 2.76], P 5 .06). As shown in Table 1 , infection rates were not different between TPE-F IGUR E 2 Kaplan Meier curves of overall survival of the Zero, Single, Multiple, and Delayed TPE cohorts. The number of events in the Zero, Single, Multiple, and Delayed TPE cohorts, respectively, was 45/204, 10/40, 19/42, and 11/27 (log-rank P value 5 .003) treated and non TPE-treated cohorts (39 vs. 37%; P 5 .82). Further, as shown in Table 2 , infection rates among the TPEtreated cohorts were similar (40% vs. 40% vs. 33% in the Single, Multiple, and Delayed TPE cohorts, respectively).
| D ISC USSI ON
In our study, we show that, at our institution, the top 3 indications for TPE in cardiac transplant patients are (1) elevated PRA or positive HLA antibodies, (2) post-transplant graft dysfunction and/or AMR, and (3) positive crossmatch. Patients who received TPE once perioperatively at transplant (Single TPE cohort) were not found to have different overall survival compared to patients who did not receive TPE (Zero TPE cohort), while patients who received postoperative TPE (Multiple and Delayed TPE cohorts) had worse overall survival compared to those who did not receive TPE (Figure 2) . Additionally, when compared to the Single TPE cohort, patients in the Multiple and Delayed TPE cohorts had worse TPE survival (Figure 3) . Finally, we show that 30-day posttransplant infection rates did not differ between the groups but was independently associated with overall survival. It is pertinent to note that the overall survival of the Zero TPE cohort is similar to that of the Single TPE cohort. Patients in the Single and, to some extent, Multiple TPE cohorts represent a group of patients for whom TPE is initiated pending final crossmatch results. This practice highlights our tendency within DUMC to utilize organs from donors to whom the recipient may have anti-HLA antibodies at a low concentration, thus allowing for a larger donor pool for pre-sensitized recipients. When these antibodies become dilute to a mean fluorescent intensity of <1000 at a 1:16 dilution, they are not considered unacceptable in the virtual crossmatch used for donor selection. However, given the possibility of a positive crossmatch, we utilize a Single TPE procedure until final crossmatch results become available. With the high likelihood that the final crossmatch results could be negative, the Single TPE cohort potentially represents a group of patients for which TPE may not be required. Strategies aimed at expediting cytolytic crossmatch results may thus save an unnecessary TPE procedure. While it remains plausible that TPE in this cohort exerts a protective effect, as the sensitivity of HLA testing increases, the risk of the low concentration antibodies would need to be better defined. Ultimately, a prospective study randomizing patients to empiric TPE or no TPE would help clarify TPE's role in this subpopulation.
Our observation of worse overall survival in the Multiple and Delayed TPE cohorts (Figure 2 ) is consistent with our expectations for the associated TPE treatment indications. Both diminished allograft and patient survival are associated with the presence of positive crossmatch, primary graft dysfunction, AMR, or elevated PRA/positive HLA antibodies. 16, 17 As shown in a retrospective study of 8160 cardiac transplant patients, elevated PRA is a significant predictor of mortality. 18 Compared to a PRA of 0%, PRA >25% conferred worse overall survival at both 1 year (94 vs. 89%; P < .001) and 5 years (71 vs. 65%; P < .001). In addition to an elevated PRA at transplant, development of AMR posttransplant decreases survival. As shown in a retrospective study of 68 heart transplant patients, survival is worst when both late AMR and graft dysfunction are present. Compared to patients with early AMR, the development of late AMR with graft dysfunction confers worse post-AMR survival at 1 and 5 years (93 vs. 64% at 1 year; 73 vs. 36% at 5 years; P < .006). 19 Further study is required to determine whether the overall survival of these subpopulations may be better improved by better monitoring tools for the presence or recurrence of AMR. In spite of the decreased survival outcomes of the Multiple and Delayed TPE cohorts, we consider these survival rates to be acceptable when compared to the survival rates of decompensated heart failure without transplant. 20, 21 The ability to accept a high-risk transplant with TPE support, rather than the certainty of death, increases the likelihood that a patient who is highly sensitized will be able to undergo a heart transplant. 22, 23 In light of the above, it is most likely that our TPEtreated patients did worse, not because they received TPE but rather, as a result of the underlying indication for which they received TPE. The role of TPE as a tool to minimize survival differences between the cohorts should be examined in future studies. To better understand TPE's impact, studies are needed to develop biomarkers of allograft improvement. These biomarkers will help tailor treatment to individual patients so that, rather than treating patients with a set number of TPE procedures, patients can be treated to maximum response.
In our study, we defined a new outcome of TPE survival. TPE survival may help us better assess the long-term success of TPE treatment because it allows us to capture a subpopulation of patients who may not have been optimally treated with the first TPE episode. In our study population, we observed that the Multiple and Delayed TPE cohorts had worse TPE survival (Figure 3) . While worse TPE survival may imply suboptimal TPE treatment, it may also suggest treatment refractoriness. Treatment refractoriness could be explained by the presence of AMR, which predisposes patients to future episodes of AMR and, ultimately, cardiac allograft vasculopathy. 24, 25 Noting that AMR is notoriously difficult to diagnose, 26 allograft vasculopathy may already be present in patients presenting with clinically apparent AMR and may contribute to lower treatment responsiveness. Further study may help clarify whether earlier TPE treatment of high risk patients may decrease future presentation with clinically significant AMR. The only variable we found to be independently associated with overall survival was 30-day post-transplant infection (Table 3 ). Other studies have similarly shown that infection increases post-transplant morbidity and mortality. 27, 28 Infection may also increase predisposition toward AMR. 29, 30 Interestingly, infection rates were similar across groups, suggesting that the use of TPE did not confer additive infectious risk. Post-transplant infectious risk is likely mediated by cardiac transplantation surgery and its associated immunosuppressive drug regimen, need for mechanical circulatory support, presence of foreign bodies, prolonged ICU stay, and ventilator dependence. [31] [32] [33] [34] [35] Although there is concern that post-transplant infectious risk may be mediated by hypogammaglobulinemia, 36 our study suggests that TPE contributes minimal risk, if any, to the already high baseline infectious risk of the cardiac transplant patient. Our study showed that in the TPE-treated cohort, both females and Blacks/African Americans were disproportionately increased. These findings are consistent with other studies that suggest that female sex is a risk factor for both AMR and decreased survival and that Black/African American race is associated with decreased survival. [37] [38] [39] Although females and African Americans were overrepresented in the TPE cohort, in our statistical model, race and sex were not found to be associated with survival (Table 3 ). This negative finding may be a function of our small numbers. However, our findings may suggest that TPE treatment of females and Blacks/African Americans at increased risk decreases transplant-associated mortality. To assess this possibility, prospective studies are needed. Of the cardiac transplantation TPE indications in our study, the only 1 categorized in the ASFA guidelines is AMR. 10 Across many studies of cardiac transplantation, AMR is a common use of TPE 2 ; however, as we found in our study, TPE is also frequently used for treatment of elevated PRA antibodies or positive HLA antibodies and positive crossmatch. 6, 7, 40 Given the high incidence of TPE use for these indications, TPE use for positive crossmatch status and positive HLA antibodies/PRA should be considered in the next iteration of the ASFA guidelines. Although the 2 most common schedules in our cohort were once perioperatively and 5 daily procedures, our study showed some variation in TPE procedure number and treatment schedule. This variation may primarily be explained by TPE indication. However, it also highlights the difficulty in determining the optimal treatment schedule and number of TPE procedures. In the literature, with regards to AMR treatment, as few as 2 and as many as 19 TPE procedures have been used. 7, 41 Additional studies are needed to determine the optimal number of TPE procedures for each TPE cardiac transplant indication and to determine whether a more individualized approach to TPE is warranted. The primary limitation of our study is that it is a retrospective analysis and cannot adequately account for all the factors that may have contributed to patient outcomes Additionally, parameters assessing TPE response, such as post-TPE HLA or PRA levels, left ventricular ejection fraction, and biopsy evaluation were not uniformly assessed across all patients, thereby limiting our ability to directly measure the impact of TPE. Finally, because TPE is used in the postcardiac transplant setting for indications that are associated with increased morbidity and mortality, the impact that TPE has on these outcomes cannot be determined from this analysis. Prospective studies are needed to clarify the impact and benefit of TPE in this complex population.
| C ONCL USI ONS
In our retrospective study of cardiac transplant patients, the most common TPE indication was elevated PRA or positive HLA antibodies. Although post-transplant infection was independently associated with overall survival, TPE did not appear to contribute to infectious risk. Prospective studies to define the role of TPE in cardiac transplant subpopulations may save unnecessary TPE procedures and help develop tailored treatment approaches to improve survival. 
